IR 902

Drug Profile

IR 902

Alternative Names: AI 208; IR-208; Multiple sclerosis vaccine - Immune Response BioPharma; NeuroVax; V beta 17

Latest Information Update: 12 Aug 2015

Price : $50

At a glance

  • Originator Immune Response Corporation
  • Developer Immune Response BioPharma; Orchestra Therapeutics
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 12 Aug 2015 Phase-II development for Multiple sclerosis is ongoing in USA
  • 06 Jan 2015 IR 902 is available for licensing as of 06 January 2015 www.immuneresponsebiopharma.com
  • 17 Jul 2014 Immune Response BioPharma plans a phase I trial for Multiple sclerosis in USA (NCT02200718)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top